Pharmas benefit from M&A news flow
City Index April 22, 2014 9:49 PM
<p>The pharmaceuticals sector has certainly been in focus today (22nd April), with shares of players within the sector having enjoyed a bit of a lift […]</p>
The pharmaceuticals sector has certainly been in focus today (22nd April), with shares of players within the sector having enjoyed a bit of a lift on the back of a series of news flow regarding M&A activity.
Some of the current buzz is, of course, based on official statements, while some has been spurred by market chatter.
What’s been announced?
UK-based GSK and Swiss-based Novartis have entered a series of transactions.
The moves, which will help bulk up Novartis’ cancer drugs portfolio and position GSK as a leader in vaccines, will see Novartis acquire GSK’s oncology business for up to $16bn and sell its vaccine business (excluding flu) to GSK for some $7bn.
Novartis, which embarked on a strategic review of its businesses last year, is also set to sell its animal health portfolio to US-based Eli Lilly for $5.4bn.
Furthermore, Novartis and GSK plan to combine their consumer healthcare businesses in a deal that would see GSK holding a majority stake (around 63%).
The market seemingly approves of the deals: Novartis is up 2.3% and GSK is up 5.5%.
Elsewhere, both Canada-based Valeant Pharmaceuticals and US-based Allergan are up – 6% and 16% respectively – following an announcement by Valeant that it’s looking to put in an offer to acquire Allergan, maker of wrinkle treatment, Botox.
UK-based AstraZeneca is up around 7% (at time of writing) following reports of a recent takeover approach.
According to reports, heavyweight, Pfizer, had been in discussions with AstraZeneca regarding a potential £60bn takeover of the UK-based company.
While those talks are said to have since ended, speculation abounds regarding another approach from Pfizer.
Now, this talk might well be without basis, particularly given the downbeat sentiment towards previous large-scale deals embarked upon by Pfizer.
Nonetheless, the idea that Pfizer – in the face of declining sales – would look to chase growth via acquisitions seems plausible and it certainly has the financial flexibility for acquisitions, should the company choose.
AstraZeneca itself has also been faced with flagging sales recently, partly as a result of loss of exclusivity on some of its brands. That’s only set to be exacerbated this year, when it loses its patent cover on its heartburn and ulcer drug, Nexium, in May.
Still, efforts to reshape the business, together with a series of drugs in the works, leads to some optimism over AstraZeneca’s mid-long-term outlook. That’s been cited as one possible reason for the interest from its larger US rival.
Meanwhile, smaller players are riding high on the back of talk that Pfizer’s (or indeed AstraZeneca’s) eyes might swivel onto one of them.
That includes Ireland-based Shire, which is currently up around 5.6%. Of course, Shire is no stranger to takeover rumours. Only last month, analysts at UBS highlighted the company as a potential takeover candidate for AstraZeneca.
Whether Shire ends up a target remains to be seen, but one thing looks certain: consolidation in the sector seems set to continue.
That bodes well for relatively smaller players with attractive portfolios – such as Shire and BTG (up 5%) – as the anticipation of a potential takeout certainly doesn’t hurt shares.
GAIN Capital UK Limited (trading as “City Index”) is an execution-only service provider. This material, whether or not it states any opinions, is for general information purposes only and it does not take into account your personal circumstances or objectives. This material has been prepared using the thoughts and opinions of the author and these may change. However, City Index does not plan to provide further updates to any material once published and it is not under any obligation to keep this material up to date. This material is short term in nature and may only relate to facts and circumstances existing at a specific time or day. Nothing in this material is (or should be considered to be) financial, investment, legal, tax or other advice and no reliance should be placed on it.
No opinion given in this material constitutes a recommendation by City Index or the author that any particular investment, security, transaction or investment strategy is suitable for any specific person. The material has not been prepared in accordance with legal requirements designed to promote the independence of investment research. Although City Index is not specifically prevented from dealing before providing this material, City Index does not seek to take advantage of the material prior to its dissemination. This material is not intended for distribution to, or use by, any person in any country or jurisdiction where such distribution or use would be contrary to local law or regulation.